QualityStocksNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing Lucid-MS, a patented first-in-class drug candidate designed to directly protect the myelin sheath damaged by multiple sclerosis (“MS”), according to an AINewsWire editorial. Unlike existing MS therapies that primarily target the immune system, Lucid-MS is a nonimmunomodulatory, neuroprotective compound intended to prevent myelin degradation. The company recently filed an Investigational New Drug application with the U.S. Food and Drug Administration and is preparing for a phase 2 clinical trial following successful completion of phase 1 safety…
